Biohit Oyj
ISIN: FI0009005482 | Ticker: BIOBV | LEI: 74370089ATTSNBXJVT29
Country: Finland
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom.
Product range consists of products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer.
1988
Served areaWorldwide
HeadquartersLaippatie 1, 880 Helsinki – Finland
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 10,777,000.00 | 9,613,000.00 | 11,015,000.00 |
| Noncurrent Assets | N/A | 2,478,000.00 | 629,000.00 | 1,115,000.00 |
| Property Plant And Equipment | N/A | 269,000.00 | 201,000.00 | 140,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 1,763,000.00 | 137,000.00 | 41,000.00 |
| Deferred Tax Assets | N/A | 17,000.00 | 14,000.00 | 22,000.00 |
| Other Noncurrent Financial Assets | N/A | 58,000.00 | 58,000.00 | 58,000.00 |
| Current Assets | N/A | 8,299,000.00 | 8,984,000.00 | 9,900,000.00 |
| Inventories | N/A | 903,000.00 | 750,000.00 | 920,000.00 |
| Trade And Other Current Receivables | N/A | 1,317,000.00 | 2,720,000.00 | 2,753,000.00 |
| Other Current Financial Assets | N/A | 5,041,000.00 | 4,413,000.00 | 4,105,000.00 |
| Cash and cash equivalents | 1,325,000.00 | 1,038,000.00 | 1,102,000.00 | 2,122,000.00 |
| Equity And Liabilities | N/A | 10,777,000.00 | 9,613,000.00 | 11,015,000.00 |
| Equity | N/A | 8,703,000.00 | 7,300,000.00 | 7,458,000.00 |
| Issued Capital | N/A | 2,350,000.00 | 2,350,000.00 | 2,350,000.00 |
| Retained Earnings | N/A | 2,468,000.00 | 979,000.00 | 1,777,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 8,703,000.00 | 7,300,000.00 | 7,458,000.00 |
| Noncurrent Liabilities | N/A | 134,000.00 | 164,000.00 | 696,000.00 |
| Deferred Tax Liabilities | N/A | 3,000.00 | 2,000.00 | 2,000.00 |
| Other Noncurrent Liabilities | N/A | 6,000.00 | 7,000.00 | 8,000.00 |
| Current Liabilities | N/A | 1,940,000.00 | 2,149,000.00 | 2,862,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 612,000.00 | 577,000.00 | 676,000.00 |
| Current Tax Liabilities Current | N/A | 256,000.00 | 66,000.00 | 257,000.00 |
| Other Current Liabilities | N/A | 1,040,000.00 | 1,324,000.00 | 1,789,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 7,123,000.00 | 9,361,000.00 | 10,951,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -144,000.00 | 305,000.00 | 16,000.00 |
| Employee Benefits Expense | 3,063,000.00 | 3,450,000.00 | 3,618,000.00 |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 1,997,000.00 | 1,988,000.00 | 481,000.00 |
| Profit Loss From Operating Activities | -3,174,000.00 | -1,480,000.00 | 1,129,000.00 |
| Finance Income | 83,000.00 | 209,000.00 | 92,000.00 |
| Finance Costs | 171,000.00 | 33,000.00 | 352,000.00 |
| Profit Loss Before Tax | -3,261,000.00 | -1,305,000.00 | 868,000.00 |
| Income Tax Expense Continuing Operations | 51,000.00 | 195,000.00 | 267,000.00 |
| Profit (loss) | -3,313,000.00 | -1,500,000.00 | 601,000.00 |
| Profit Loss Attributable To Owners Of Parent | -3,313,000.00 | -1,500,000.00 | 601,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -3,313,000.00 | -1,500,000.00 | 601,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 2,146,000.00 | 1,976,000.00 | 1,199,000.00 |
| Adjustments For Income Tax Expense | N/A | 51,000.00 | 195,000.00 | 267,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 97,000.00 | 161,000.00 | -165,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 0.00 | -3,000.00 | -2,000.00 |
| Other Adjustments For Noncash Items | N/A | 11,000.00 | -12,000.00 | 206,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 2,146,000.00 | 1,976,000.00 | 1,199,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 103,000.00 | 25,000.00 | 106,000.00 |
| Interest Received Classified As Operating Activities | N/A | 98,000.00 | 120,000.00 | 122,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 142,000.00 | 18,000.00 | 313,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -25,000.00 | -444,000.00 | 1,848,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -35,000.00 | 760,000.00 | -625,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 222,000.00 | 266,000.00 | 186,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -222,000.00 | -266,000.00 | -186,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -282,000.00 | 50,000.00 | 1,036,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -5,000.00 | 13,000.00 | -16,000.00 |
| Cash and cash equivalents | 1,325,000.00 | 1,038,000.00 | 1,102,000.00 | 2,122,000.00 |
Please note that some sums might not add up.
FI0009005482
LEI74370089ATTSNBXJVT29
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.